Anthranilic Acid

Anthranilic Acid

SCHEMBL2245820

Nc1ccccc1C(=O)[O-].O=C([O-])C=Cc1c[nH]cn1.[Zn+2]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.37
▸ ALDH1A1 P00352 5/20 0.35
▸ HSD17B10 Q99714 4/20 0.35
▸ TSHR P16473 2/20 0.35
▸ HDAC1 Q13547 2/20 0.33
▸ HDAC2 Q92769 2/20 0.33
▸ NPC1 O15118 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ RELA Q04206 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthranilic Acid SCHEMBL2244669 0.99 MAPT (0.38) MAPTALDH1A1HSD17B10TSHRHDAC1
Anthranilic Acid SCHEMBL2245890 0.97 MAPT (0.37) MAPTALDH1A1HSD17B10TSHRHDAC1
Anthranilic Acid SCHEMBL2243275 0.89 MAPT (0.42) MAPTALDH1A1HSD17B10TSHRHDAC1
Cis-Urocanic Acid SCHEMBL2247224 0.86 KDM4E (0.47) MAPTALDH1A1HSD17B10TSHRNPC1
Cis-Urocanic Acid SCHEMBL2242986 0.86 KDM4E (0.47) MAPTALDH1A1NPC1HPGDRAB9A
Cis-Urocanic Acid SCHEMBL2245677 0.84 KDM4E (0.47) MAPTALDH1A1NPC1HPGDRAB9A
Cis-Urocanic Acid SCHEMBL2249970 0.82 — —
Cis-Urocanic Acid SCHEMBL2246447 0.82 — —
Cis-Urocanic Acid SCHEMBL15419 0.79 — —
Cis-Urocanic Acid SCHEMBL9614484 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7993630-B2 Protection of skin from UV and peroxide BIODERM RESEARCH (US) 2011-08-09 — — US claimed
US-20090269291-A1 Protection of Skin from UV and Peroxide BIODERM RESEARCH (US) 2009-10-29 — — US claimed
US-7993630-B2 Protection of skin from UV and peroxide BIODERM RESEARCH (US) 2011-08-09 — — US disclosed
US-20090269291-A1 Protection of Skin from UV and Peroxide BIODERM RESEARCH (US) 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269291-A1 Protection of Skin from UV and Peroxide SOD3, UROD, SOD1 MAPT 1019/4885ALDH1A1 1367/4885HSD17B10 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback